Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 287

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 8
Chunk 287
---
 License and collaboration revenue

    —

    687

    Total revenue

    128,940

    8,573

    Costs and operating expenses:

    Cost of commercialization revenue

    21,009

    8,886

    Research and development expenses

    151,483

    224,785

    General and administrative expenses

    39,886

    50,908

    Total costs and operating expenses

    212,378

    284,579

    Loss from operations

    (83,438
    )

    (276,006
    )

    Other income (expense), net:

    Interest income

    2,110

    5,426

    Interest expense

    (4,615
    )

    (5,285
    )

    Other income (expense), net:

    528

    (246
    )

    Total other income (expense), net

    (1,977
    )

    (105
    )

    Loss before provision for (benefit from) income taxes

    (85,415
    )

    (276,111
    )

    Provision for (benefit from) income taxes

    (12
    )

    15

    Net loss
     
    $
    (85,403
    )
     
    $
    (276,126
    )

    Other comprehensive gain (loss):

    Unrealized gain (loss) on available-for-sale securities

    212

    1,863

    Comprehensive loss
     
    $
    (85,191
    )
     
    $
    (274,263
    )

    Basic and diluted net loss per common share
     
    $
    (11.41
    )
     
    $
    (65.19
    )

    Basic and diluted weighted-average shares outstanding

    7,488

    4,236

 See accompanying notes to the consolidated financial statements.

100

Atara Biotherapeutics, Inc. 

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

(In thousands)

    Accumulated

    Common

    Additional

    Other

    Total

    Stock

    Paid-in

    Comprehensive

    Accumulated

    Stockholders’

    Shares

    Amount

    Capital

    (Loss) Income

    Deficit

    Equity (Deficit)

    Balance as of January, 1 2023